Abstract
Enhanced DNA repair in many cancer cells can be correlated to the resistance to cancer treatment, and thus contributes to a poor prognosis. Ionizing radiation and many anti-cancer drugs induce DNA double-strand breaks (DSBs), which are usually regarded as the most toxic types of DNA damages. Repair of DNA DSBs is vital for maintaining genomic stability and hence crucial for survival and propagation of all cellular organisms. Therefore, reducing the capacity of cancer cells to repair DSBs could sensitize tumors to radio/chemotherapy. Many investigators have used gene therapy strategies to down-regulate or inactivate proteins involved in the repair of DSBs in order to reduce the survival of cancer cells. Herein, are reviewed several protein candidates that have been targeted by different gene therapy approaches. Results obtained from in vitro and in vivo experiments are presented and discussed in the perspective of potential gene therapy clinical trials.
Keywords: Antisense, siRNA, radiosensitization, ionizing radiation, chemotherapy, NHEJ, homologous recombination, double-strand break
Current Gene Therapy
Title: Targeting DNA Repair Proteins: A Promising Avenue for Cancer Gene Therapy
Volume: 6 Issue: 1
Author(s): Jean-Philippe Belzile, Sibgat A. Choudhury, Denis Cournoyer and Terry Y.-K. Chow
Affiliation:
Keywords: Antisense, siRNA, radiosensitization, ionizing radiation, chemotherapy, NHEJ, homologous recombination, double-strand break
Abstract: Enhanced DNA repair in many cancer cells can be correlated to the resistance to cancer treatment, and thus contributes to a poor prognosis. Ionizing radiation and many anti-cancer drugs induce DNA double-strand breaks (DSBs), which are usually regarded as the most toxic types of DNA damages. Repair of DNA DSBs is vital for maintaining genomic stability and hence crucial for survival and propagation of all cellular organisms. Therefore, reducing the capacity of cancer cells to repair DSBs could sensitize tumors to radio/chemotherapy. Many investigators have used gene therapy strategies to down-regulate or inactivate proteins involved in the repair of DSBs in order to reduce the survival of cancer cells. Herein, are reviewed several protein candidates that have been targeted by different gene therapy approaches. Results obtained from in vitro and in vivo experiments are presented and discussed in the perspective of potential gene therapy clinical trials.
Export Options
About this article
Cite this article as:
Belzile Jean-Philippe, Choudhury A. Sibgat, Cournoyer Denis and Chow Y.-K. Terry, Targeting DNA Repair Proteins: A Promising Avenue for Cancer Gene Therapy, Current Gene Therapy 2006; 6 (1) . https://dx.doi.org/10.2174/156652306775515538
DOI https://dx.doi.org/10.2174/156652306775515538 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Macrophage-Assisted Inflammation and Pharmacological Regulation of the Cholinergic Anti-Inflammatory Pathway
Current Medicinal Chemistry Molecular Signatures of Biomarkers in Cancer Development, Diagn osis, and its Prognostic Accuracy
Current Biomarkers (Discontinued) Anti-Cancer Effects of a New Docosahexaenoic Acid Monoacylglyceride in Lung Adenocarcinoma
Recent Patents on Anti-Cancer Drug Discovery Editorial (Thematic Issue: Chemoresistance in Gynecologic Cancers)
Current Cancer Therapy Reviews Personalized Peptide Vaccine for Treatment of Advanced Cancer
Current Medicinal Chemistry Two Diseases with One Hit: Inhibiting a Potential Diabetes Target to Reduce Cancer Risk and to Improve Anti-Cancer Therapy
Current Cancer Therapy Reviews Poxvirus Cancer Therapy
Recent Patents on Anti-Infective Drug Discovery Nanostructured Lipid Carriers (NLCs) for Drug Delivery: Role of Liquid Lipid (Oil)
Current Drug Delivery Critical Functions of lncRNA DGCR5 in Cancers of the Digestive System
Current Pharmaceutical Design Skp2 Inhibitors: Novel Anticancer Strategies
Current Medicinal Chemistry Formulation and Characterization of Rutin Loaded Chitosan-alginate Nanoparticles: Antidiabetic and Cytotoxicity Studies
Current Drug Delivery Infectious Co-Factors in HIV-1 Transmission Herpes Simplex Virus Type-2 and HIV-1: New Insights and Interventions
Current HIV Research Treatment of Chronic Hypercalcemia
Medicinal Chemistry Antiviral Activities of Human Host Defense Peptides
Current Medicinal Chemistry Protective Effects of Downregulating Estrogen Receptor Alpha Expression in Cervical Cancer
Anti-Cancer Agents in Medicinal Chemistry Assessment of Expression of Homeobox A5 in Endometrial Cancer on the mRNA and Protein Level
Current Pharmaceutical Biotechnology Targeting the PI3K/Akt/mTOR Axis by Apigenin for Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Application of Intrabodies Against Age-Related Neurodegenerative Disorders
Current Pharmaceutical Design Uncommon Becoming Common: Case Series of Primary Fallopian Tube Cancers
Current Women`s Health Reviews Near-infrared Light Responsive Upconversion Nanoparticles for Imaging, Drug Delivery and Therapy of Cancers
Current Nanoscience